Filings
| Filing | Date | Type | Filed with |
|---|
| Consolidated Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2027 (IFRS) | Oct 28, 2026 | Results | Tokyo Stock Exchange |
|---|
| 2nd Quarter of Fiscal Year 2026 (Ending March 31, 2027) (April 1, 2026 to September 30, 2026) Supplementary Materials (Consolidated IFRS) | Oct 28, 2026 | Results | Tokyo Stock Exchange |
|---|
| Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN | Oct 8, 2026 | Acquisition or disposal | Tokyo Stock Exchange |
|---|
| Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (IFRS) | Jul 30, 2026 | Results | Tokyo Stock Exchange |
|---|